Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.24.11 (CD10)
 9,792 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Objective To investigate the relationship between long-chain intergenic non-coding RNA324 (LINC00324) and immunophenotype in peripheral blood leukocytes of acute myeloid leukemia (AML) patients. Methods Real-time quantitative PCR and bioinformatics databases were utilized to analyze the expression level of LINC00324 in peripheral blood leukocytes and cell lines KG-1, THP-1 and U937 in AML patients. The relationships of the expression level of LINC00324 with the red blood cell and platelet count, the expression levels of LINC00324 and immunophenotypes in 40 AML patients were analyzed by Person correlation analysis. The immunophenotypes included CD14, CD68, CD64, CD11b, CD4, CD45, CD33, HLA-DR, CD163, CD2, CD58, CD117, CD43, CD34, CD99, CD8, CD38, CD10, CD13, CD56, CD7, TdT, CD235a, CD138, CD61, MPO and CD19. Simultaneously, the cBioPortal database datasets (TCGA, NEJM 2013) were used to analyze the clinical characteristics of 173 AML patients, and to analyze the correlations between the expression level of LINC00324 and the peripheral blood blast percentage and white blood cell count in tumor samples. Results The expression of LINC00324 in peripheral blood leukocytes of AML patients was down-regulated, and its expression level was significantly correlated with immunophenotype CD33, red blood cell and platelet count. Analysis of bioinformatics database showed that LINC00324 was under-expressed in myeloid leukemia cell lines. The expression of LINC00324 in AML patients was associated with multiple immunophenotypes such as CD33, CD117, CD11b, CD14 and CD64 and was negatively correlated with peripheral blood blast percentage and white blood cell count. Conclusion LINC00324 may be involved in regulating the differentiation, development and function of immune cells, which providing a new strategy for the development of targeted drugs or treatment of AML.
 ...
PMID:[Correlation analysis between LINC00324 and immunophenotype in peripheral blood leukocytes in patients with acute myeloid leukemia]. 3175 Aug 27

Minimal/Measurable residual disease (MRD) is the most reliable and powerful indicator of prognosis in B cell precursor acute lymphoblastic leukemia (BCP-ALL). Modulation of antigenic expression in leukemic cells is known to occur postchemotherapy and thus carries a potential risk of false MRD quantification by flowcytometry. We studied the immunophenotypic modulation of nine antigens in residual leukemic cells at postinduction MRD assessment in 31 BCP - ALL children. We found significant downmodulation of CD10, CD38, CD58, CD81 and upmodulation of CD19, CD45 in leukemic cells. Downmodulation of CD34 was observed but was not statistically significant. Expression of CD20 and CD22 remained stable in most of the cases. MRD-positive cases showed loss of diagnostic LAIP and some showed gain of new LAIP compared to baseline. Various combination of antibodies including the novel markers should be incorporated into the panel to increase the sensitivity of MRD detection.
 ...
PMID:Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection. 3228 3


<< Previous 1 2 3